Information Provided By: 
Fly News Breaks for March 18, 2019
AGN, BHVN
Mar 18, 2019 | 09:38 EDT
Biohaven Pharmaceutical's purchase of a priority review voucher puts rimegepant orally dissolving tablet on track for a potential approval by year-end, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Depending on when the new drug application is filed over the next four months, a rimegepant approval could potentially leapfrog Allergan's (AGN) ubrogepant, says the analyst. He views rimegepant as the "best-in-class oral CGRP" and keeps an Overweight rating on Biohaven with a $75 price target.
News For BHVN;AGN From the Last 2 Days
BHVN
Apr 17, 2024 | 16:10 EDT
BHVN
Apr 17, 2024 | 16:09 EDT
BHVN
Apr 17, 2024 | 11:00 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Soligenix (SNGX),... To see the rest of the story go to thefly.com. See Story Here
